1467 related articles for article (PubMed ID: 16490582)
21. Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study.
Yu S; Shen W; Yu L; Hou Y; Han J; Richards HM
J Pain; 2014 Aug; 15(8):835-44. PubMed ID: 24846822
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study.
Hartrick C; Van Hove I; Stegmann JU; Oh C; Upmalis D
Clin Ther; 2009 Feb; 31(2):260-71. PubMed ID: 19302899
[TBL] [Abstract][Full Text] [Related]
23. Clinical efficacy and safety of once-daily dosing of a novel, prolonged-release oral morphine tablet compared with twice-daily dosing of a standard controlled-release morphine tablet in patients with cancer pain: a randomized, double-blind, exploratory crossover study.
Ridgway D; Sopata M; Burneckis A; Jespersen L; Andersen C
J Pain Symptom Manage; 2010 Apr; 39(4):712-20. PubMed ID: 20413058
[TBL] [Abstract][Full Text] [Related]
24. Titration with oxymorphone extended release to achieve effective long-term pain relief and improve tolerability in opioid-naive patients with moderate to severe pain.
Rauck R; Ma T; Kerwin R; Ahdieh H
Pain Med; 2008 Oct; 9(7):777-85. PubMed ID: 18950436
[TBL] [Abstract][Full Text] [Related]
25. From codeine to transdermal fentanyl for cancer pain control: a safety and efficacy clinical trial.
Mystakidou K; Befon S; Kouskouni E; Gerolymatos K; Georgaki S; Tsilika E; Vlahos L
Anticancer Res; 2001; 21(3C):2225-30. PubMed ID: 11501851
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic and pharmacodynamic properties of tramadol IR and SR in elderly patients: a prospective, age-group-controlled study.
Likar R; Wittels M; Molnar M; Kager I; Ziervogel G; Sittl R
Clin Ther; 2006 Dec; 28(12):2022-39. PubMed ID: 17296459
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis.
Hale M; Tudor IC; Khanna S; Thipphawong J
Clin Ther; 2007 May; 29(5):874-888. PubMed ID: 17697906
[TBL] [Abstract][Full Text] [Related]
28. Randomized clinical trial comparing a patient-driven titration protocol of intravenous hydromorphone with traditional physician-driven management of emergency department patients with acute severe pain.
Chang AK; Bijur PE; Davitt M; Gallagher EJ
Ann Emerg Med; 2009 Oct; 54(4):561-567.e2. PubMed ID: 19560838
[TBL] [Abstract][Full Text] [Related]
29. A randomized, double-blind, 8-week crossover study of once-daily controlled-release tramadol versus immediate-release tramadol taken as needed for chronic noncancer pain.
Beaulieu AD; Peloso P; Bensen W; Clark AJ; Watson CP; Gardner-Nix J; Thomson G; Piraino PS; Eisenhoffer J; Harsanyi Z; Darke AC
Clin Ther; 2007 Jan; 29(1):49-60. PubMed ID: 17379046
[TBL] [Abstract][Full Text] [Related]
30. Outcomes after intravenous opioids in emergency patients: a prospective cohort analysis.
O'Connor AB; Zwemer FL; Hays DP; Feng C
Acad Emerg Med; 2009 Jun; 16(6):477-87. PubMed ID: 19426295
[TBL] [Abstract][Full Text] [Related]
31. Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial.
Matsumoto AK; Babul N; Ahdieh H
Pain Med; 2005; 6(5):357-66. PubMed ID: 16266356
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period.
Kress HG; Orońska A; Kaczmarek Z; Kaasa S; Colberg T; Nolte T
Clin Ther; 2009 Jun; 31(6):1177-91. PubMed ID: 19695386
[TBL] [Abstract][Full Text] [Related]
33. [Effects of sustained release morphine hydrochloride tablets in management of cancer pain: a survey of 567 patients].
Yu SY; Qiu H; Ma ZS; Chen J; Zhang Y; Chen LZ; Wang DL; Ma ZY
Zhonghua Yi Xue Za Zhi; 2004 Mar; 84(6):450-5. PubMed ID: 15061959
[TBL] [Abstract][Full Text] [Related]
34. Codeine/acetaminophen and hydrocodone/acetaminophen combination tablets for the management of chronic cancer pain in adults: a 23-day, prospective, double-blind, randomized, parallel-group study.
Rodriguez RF; Castillo JM; Del Pilar Castillo M; Nuñez PD; Rodriguez MF; Restrepo JM; Rodriguez JM; Ortiz Y; Angel AM
Clin Ther; 2007 Apr; 29(4):581-7. PubMed ID: 17617281
[TBL] [Abstract][Full Text] [Related]
35. Open-label study to evaluate the efficacy and safety of extended-release hydromorphone in patients with chronic neuropathic pain.
Nalamachu S; Ruck D; Nalamasu R; Fasbinder S; Bansal R
J Opioid Manag; 2013; 9(1):43-9. PubMed ID: 23709303
[TBL] [Abstract][Full Text] [Related]
36. A randomized study to demonstrate noninferiority of once-daily OROS(®) hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain.
Binsfeld H; Szczepanski L; Waechter S; Richarz U; Sabatowski R
Pain Pract; 2010; 10(5):404-15. PubMed ID: 20384968
[TBL] [Abstract][Full Text] [Related]
37. Dose conversion between tapentadol immediate and extended release for low back pain.
Etropolski MS; Okamoto A; Shapiro DY; Rauschkolb C
Pain Physician; 2010; 13(1):61-70. PubMed ID: 20119464
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the abuse potential of extended release hydromorphone versus immediate release hydromorphone.
Shram MJ; Sathyan G; Khanna S; Tudor IC; Nath R; Thipphawong J; Sellers EM
J Clin Psychopharmacol; 2010 Feb; 30(1):25-33. PubMed ID: 20075644
[TBL] [Abstract][Full Text] [Related]
39. Opioid titration and conversion in patients receiving morphine sulfate and naltrexone hydrochloride extended release capsules.
Webster LR; Brewer R; Morris D; Cleveland JM; Setnik B
Postgrad Med; 2011 Sep; 123(5):155-64. PubMed ID: 21904098
[TBL] [Abstract][Full Text] [Related]
40. [Controlled-release hydromorphone in elderly patients with severe pain of different etiologies. Results of an observational study].
Junker U; Figge V
MMW Fortschr Med; 2005 Oct; 147 Suppl 3():91-6. PubMed ID: 16261943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
